ViroMed Builds Team of Experts to Direct Global Drug Development and Commercialization Efforts

Experts in Pain-Related Clinical Development, Marketing, and Market Access Join ViroMed To Prepare for Launch of VM202 in the United States

Nov 17, 2017 – SEOUL, Korea - ViroMed (KOSDAQ 084990), a biotech company developing novel biologics, announced on November 7th that it has built a global team of experts to add momentum to the global development and commercialization of VM202 by recruiting Dr. William Schmidt, Dr. Cathryn Carroll, and Dr. Marie-Laure Nevoret.   

Dr. William Schmidt, Ph.D., is now responsible for overseeing ViroMed’s U.S. clinical trials evaluating VM202, a proprietary, DNA-based biopharmaceutical product targeting DPN, PAD and ALS, as Director of the Global Clinical Development Unit. Dr. Schmidt has more than 30 years of experience in developing pain-related medicines with special expertise in clinical studies and regulation. He is also President of NorthStar Consulting, an agency that provides consulting services to pharmaceutical and bioengineering companies around the world on pre-clinical and clinical studies for innovative pain medications. Dr. Schmidt has also served as President at Catalina Pharma, Vice President for clinical development at EicOsis, and Chief Medical Officer at Ensysce Biosciences.

Dr. Marie-Laure Nevoret, MD, is a surgeon and clinical researcher specializing in diabetic periphery neuropathy (DPN), whose role at ViroMed is to support and operate VM202 clinical trials in the U.S with Dr. Schmidt.

Dr. Cathryn (Cathy) Carroll, Ph.D., has joined ViroMed’s Strategic Business Development Team to strengthen the team’s capability of global marketing and business development while overseeing VM202’s licensing-out process. Dr. Carroll is leading the company’s global marketing and communication efforts by pursuing a variety of business partnerships and licensing-out while introducing new pipelines and establishing pre-commercialization strategies of VM202 in market entry, pricing, market access, public relations, and investor relations. With B.S. in Pharmacy, MBA, and Ph.D. in Economics, Dr. Carroll’s expertise spans various fields and disciplines. She has worked across the spectrum of stakeholders involved in the development, commercialization, and formulary approval of pharmaceutical products. After receiving her PhD in Economics, Dr. Carroll served as a Senior Director for Commercial Consulting and Market Access at Xcenda and within the Global Health Economics & Outcomes Research at Teva Pharmaceutical. Earlier in her career she worked as a sales representative for Eli Lilly & Co and within hospitals and health plans where she was tasked with leading formulary decision making efforts.  

ViroMed CEO Yongsoo Kim explained the significance of securing an additional lineup of global experts to lead future clinical development, market access and commercialization efforts. “Multinational pharmaceutical companies have multi-faceted strategies to position themselves with a competitive edge in the market. We must not only evolve our clinical development strategies to meet FDA/EMA requirements but must also secure the data and insights needed for the optimal adoption of VM202 at launch. We believe our launch will be more successful if we have the right data and an informed, targeted, and well executed consumer, healthcare practitioner and payer-oriented commercial campaign. Given the success of the Phase II and Phase III programs, it was determined that now was the time to find, recruit and hire the talent we needed to execute on each of these strategic imperatives."

Willian Schmidt, Ph.D.

• President, NorthStar Consulting, LLC
• Chief Medical Officer / VP Regulatory and Clinical, Signature Therapeutics / Ensysce Biosciences
• Vice President, Regulatory and Clinical, Centrexion Corporation / Arcion Therapeutics, Inc.
• Principal Research Scientist, Senior Research Associate, the DuPont Merck Pharmaceutical Co.
• Post Doc. Boston University School of Medicine
• Ph.D. in Pharmacology, UCSF
• A.B. in Biochemistry, UC Berkeley

Marie-Laure Nevoret, MD

• Medical Director / Impeto Medical, Inc.
• Doctor of Medicine, Loyola University Stritch School of Medicine
• B.A. in Chemistry, Duke

Cathryn (Cathy) A. Carroll, PhD, MA, MBA, BSPharm

• Xcenda, LLC. Senior Director, Commercial Consulting and Market Access
• Teva Pharmaceutical Inc., Associate Director, Global Health Economics & Outcomes Research
• Comprehensive Pharmacy Services, Director of Pharmacy
• University of Missouri-Kansas City, Assistant Professor, Division of Pharmacy Practice
• PhD in Economics, University of Kansas
• MA in Economics, University of Kansas
• MBA in University of Missouri-Kansas City
• BS in Pharmacy, University of Missouri-Kansas City